X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8553) 8553
Newsletter (792) 792
Book Review (789) 789
Publication (560) 560
Conference Proceeding (68) 68
Magazine Article (47) 47
Dissertation (35) 35
Newspaper Article (30) 30
Book Chapter (21) 21
Government Document (12) 12
Paper (5) 5
Trade Publication Article (5) 5
Web Resource (3) 3
Book / eBook (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
celecoxib (8676) 8676
index medicus (5827) 5827
humans (4448) 4448
male (2458) 2458
female (2155) 2155
animals (2114) 2114
cox-2 inhibitors (1603) 1603
sulfonamides - pharmacology (1521) 1521
nonsteroidal antiinflammatory drugs (1489) 1489
angiogenesis inhibitors (1466) 1466
pharmacology & pharmacy (1432) 1432
sulfonamides - therapeutic use (1330) 1330
middle aged (1325) 1325
oncology (1317) 1317
pyrazoles - pharmacology (1183) 1183
cyclooxygenase-2 (1138) 1138
cancer (1134) 1134
aged (1124) 1124
adult (1046) 1046
pyrazoles (1039) 1039
research (981) 981
rats (939) 939
apoptosis (909) 909
mice (909) 909
pyrazoles - therapeutic use (892) 892
expression (885) 885
anti-inflammatory agents, non-steroidal - adverse effects (879) 879
sulfonamides - adverse effects (865) 865
anti-inflammatory agents, non-steroidal - therapeutic use (840) 840
cyclooxygenase 2 inhibitors - pharmacology (834) 834
osteoarthritis (823) 823
cyclooxygenase 2 (813) 813
rofecoxib (789) 789
rheumatoid-arthritis (786) 786
cox-2 (778) 778
nonsteroidal anti-inflammatory drugs (751) 751
cyclooxygenase inhibitors - therapeutic use (747) 747
cyclooxygenase inhibitors - pharmacology (744) 744
sulfonamides - administration & dosage (737) 737
cyclooxygenase 2 - metabolism (699) 699
inflammation (691) 691
analysis (690) 690
care and treatment (687) 687
cyclooxygenase 2 inhibitors (685) 685
cyclooxygenase 2 inhibitors - therapeutic use (662) 662
treatment outcome (655) 655
abridged index medicus (631) 631
cell line, tumor (618) 618
prevention (604) 604
membrane proteins (585) 585
pyrazoles - administration & dosage (584) 584
drugs (568) 568
cyclooxygenase inhibitors - adverse effects (567) 567
drug therapy (567) 567
risk (550) 550
dose-response relationship, drug (522) 522
risk factors (510) 510
cyclooxygenase-2 inhibitor (503) 503
apoptosis - drug effects (490) 490
medicine, general & internal (485) 485
pyrazoles - adverse effects (478) 478
anti-inflammatory agents, non-steroidal - pharmacology (472) 472
double-blind method (437) 437
double-blind (433) 433
aged, 80 and over (420) 420
isoenzymes - antagonists & inhibitors (410) 410
gastrointestinal toxicity (409) 409
pain (409) 409
aspirin (408) 408
cell proliferation - drug effects (389) 389
cyclooxygenase 2 inhibitors - administration & dosage (386) 386
arthritis (383) 383
nsaids (383) 383
cyclooxygenase 2 inhibitors - adverse effects (380) 380
inhibition (376) 376
chemoprevention (372) 372
biochemistry & molecular biology (368) 368
medicine & public health (367) 367
chemistry, medicinal (362) 362
inhibitors (360) 360
rheumatology (355) 355
clinical trials (353) 353
health aspects (352) 352
in-vitro (351) 351
disease models, animal (349) 349
reports (348) 348
rats, sprague-dawley (346) 346
naproxen (344) 344
gastroenterology & hepatology (337) 337
time factors (332) 332
chemotherapy (331) 331
medicine, research & experimental (321) 321
anti-inflammatory agents, non-steroidal - administration & dosage (320) 320
cyclooxygenase-2 inhibitors (318) 318
sulfones (318) 318
cells (313) 313
drug therapy, combination (313) 313
growth (312) 312
surgery (310) 310
cyclooxygenase (309) 309
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8999) 8999
Chinese (103) 103
German (94) 94
French (82) 82
Spanish (73) 73
Korean (36) 36
Russian (33) 33
Japanese (31) 31
Italian (17) 17
Portuguese (16) 16
Croatian (8) 8
Persian (7) 7
Turkish (6) 6
Czech (5) 5
Danish (5) 5
Polish (5) 5
Norwegian (4) 4
Dutch (3) 3
Slovak (3) 3
Swedish (3) 3
Hungarian (2) 2
Finnish (1) 1
Lithuanian (1) 1
Romanian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 11/1999, Volume 282, Issue 20, pp. 1921 - 1928
CONTEXT In vitro studies have shown that celecoxib inhibits cyclooxygenase 2 (COX-2) but not COX-1, suggesting that this drug may have anti-inflammatory and... 
SELECTIVE-INHIBITION | MEDICINE, GENERAL & INTERNAL | SYNTHASE CYCLOOXYGENASE | MESSENGER-RNA | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | IN-VIVO | PROSTAGLANDIN SYNTHASE | PHORBOL ESTER | EXPRESSION | PEPTIC-ULCER DISEASE | CYCLOOXYGENASE-2 INHIBITOR | Prospective Studies | Cyclooxygenase 2 | Humans | Middle Aged | Cyclooxygenase 1 | Male | Intestinal Mucosa - drug effects | Arthritis, Rheumatoid - drug therapy | Prostaglandin-Endoperoxide Synthases | Analgesics, Non-Narcotic - adverse effects | Gastric Mucosa - drug effects | Peptic Ulcer - diagnosis | Adult | Female | Naproxen - adverse effects | Double-Blind Method | Duodenum | Isoenzymes | Pyrazoles | Endoscopy, Gastrointestinal | Analgesics, Non-Narcotic - therapeutic use | Celecoxib | Naproxen - therapeutic use | Membrane Proteins | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cyclooxygenase 2 Inhibitors | Analysis of Variance | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Sulfonamides - adverse effects | Aged | Peptic Ulcer - chemically induced | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - therapeutic use | Evaluation | Nonsteroidal anti-inflammatory drugs | Drug therapy | Rheumatoid arthritis | Medical research | Rheumatism | Arthritis | Analgesics | naproxen | celecoxib | Index Medicus | Abridged Index Medicus
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 08/2016, Volume 118, pp. 250 - 258
Two new series of 1,5-diaryl pyrazoles ( , , , and ) and 1,5-diaryl pyrazoline ( and were prepared as both Cyclooxygenase-2 and 15-lipoxygenase inhibitors.... 
15-Lipoxygenase inhibitors | Ethyl trifloroacetate | SO2NH2 pharmacophores | Cyclooxygenase inhibitors | Celecoxib analogues | DMFDMA | Anti-inflammatory | pharmacophores | CHEMISTRY, MEDICINAL | COX-2 | LEUKOTRIENES | CYCLOOXYGENASE | PROSTAGLANDINS | INFLAMMATION | BIOLOGICAL EVALUATION | AGENTS | 5-LIPOXYGENASE | MEDIATORS | DERIVATIVES | Stereoisomerism | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Male | Cyclooxygenase 2 Inhibitors - chemistry | Celecoxib - chemistry | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Cyclooxygenase 2 Inhibitors - adverse effects | Lipoxygenase Inhibitors - chemical synthesis | Pyrazoles - chemistry | Lipoxygenase Inhibitors - chemistry | Cattle | Celecoxib - chemical synthesis | Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis | Celecoxib - adverse effects | Cyclooxygenase 2 Inhibitors - chemical synthesis | Chemistry Techniques, Synthetic | Cyclooxygenase 2 Inhibitors - pharmacology | Magnetic Resonance Spectroscopy | Rats | Celecoxib - pharmacology | Arachidonate 15-Lipoxygenase - metabolism | Lipoxygenase Inhibitors - adverse effects | Ulcer - chemically induced | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cyclization | Cyclooxygenase 2 - metabolism | Thiazoles - chemistry | Lipoxygenase Inhibitors - pharmacology | COX-2 inhibitors | Carrageenin | Nuclear magnetic resonance | Celecoxib | Angiogenesis inhibitors | Liability (Law) | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10087, pp. 2375 - 2382
Summary Background Present guidelines are conflicting for patients at high risk of both cardiovascular and gastrointestinal events who continue to require... 
Internal Medicine | RHEUMATOID-ARTHRITIS | CYCLO-OXYGENASE-2 | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | PHARMACOLOGY | DICLOFENAC | PREVENTION | RISK | OSTEOARTHRITIS | Celecoxib - administration & dosage | Recurrence | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Secondary Prevention - methods | Aspirin - administration & dosage | Cyclooxygenase 2 Inhibitors - adverse effects | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Naproxen - administration & dosage | Cyclooxygenase 2 Inhibitors - therapeutic use | Peptic Ulcer Hemorrhage - prevention & control | Aged, 80 and over | Aspirin - therapeutic use | Drug Therapy, Combination | Celecoxib - adverse effects | Naproxen - adverse effects | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Cyclooxygenase 2 Inhibitors - administration & dosage | Peptic Ulcer Hemorrhage - chemically induced | Celecoxib - therapeutic use | Proton Pump Inhibitors - therapeutic use | Naproxen - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Arthritis - drug therapy | Aged | Care and treatment | Aspirin | Anti-inflammatory drugs | Gastrointestinal diseases | Naproxen | Clinical trials | Arthritis | Complications and side effects | Medical research | Gastrointestinal bleeding | Medicine, Experimental | Drugs | Funding | Risk | Population studies | Hemorrhage | Bleeding | Incidence | Prostaglandin endoperoxide synthase | Motivation | Safety | Nonsteroidal anti-inflammatory drugs | Antiinflammatory agents | Digestive system | Risk reduction | Inflammation | Celecoxib | Patients | Nonsteroidal antiinflammatory drugs | Diseases | Omeprazole | Random numbers | Inhibitors | Ulcers | Healing | Fatalities | Cyclooxygenase-2 | Cardiovascular diseases | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 9/2017, Volume 34, Issue 9, pp. 1956 - 1969
In the current work, we propose a combined delivery nanoplatform for letrozole (LTZ) and celecoxib (CXB).Multi-reservoir nanocarriers were developed by... 
Biochemistry, general | letrozole | Biomedical Engineering | Biomedicine | phospholipid complexation | celecoxib | Pharmacy | Medical Law | Pharmacology/Toxicology | combined delivery | multi-reservoir nanocarriers | CELLS | DESIGN | PROTEIN | ACID | DRUG-DELIVERY | FLUTAMIDE | FORMULATION | CHEMISTRY, MULTIDISCIPLINARY | IN-VITRO | LINKED CASEIN NANOPARTICLES | LIQUID-CRYSTALLINE NANOPARTICLES | PHARMACOLOGY & PHARMACY | Celecoxib - administration & dosage | Triazoles - administration & dosage | Nitriles - pharmacology | Humans | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Nanocapsules - chemistry | Nitriles - pharmacokinetics | Drug Carriers - chemistry | Nitriles - administration & dosage | MCF-7 Cells | Female | Triazoles - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Celecoxib - pharmacokinetics | Triazoles - therapeutic use | Protamines - chemistry | Phospholipids - chemistry | Celecoxib - pharmacology | Celecoxib - therapeutic use | Breast Neoplasms - drug therapy | Rats, Sprague-Dawley | Triazoles - pharmacology | Animals | Breast Neoplasms - pathology | Mice, Inbred BALB C | Drug Combinations | Nitriles - therapeutic use | Care and treatment | Endothelial growth factors | Analysis | Breast cancer | Phospholipids | Celecoxib | Angiogenesis inhibitors | Health aspects | Blood proteins | Cancer | Encapsulation | Drugs | Intravenous administration | Toxicity | Cytotoxicity | Serum proteins | Anticancer properties | Proteins | Angiogenesis | Reduction | Rodents | Aromatase | Core-shell structure | Inhibition | Mammary gland | Drug therapy | Vascular endothelial growth factor | Protective coatings | Surface charge | Rats | Caspase | Pharmacology | Nanostructure | Protamine | Tumor necrosis factor | Breast | Reservoirs | Mice | Ascites | Circulation | Tumors | Apoptosis | Index Medicus
Journal Article
Orthopedic Journal of China, ISSN 1005-8478, 09/2010, Volume 18, Issue 18, pp. 1550 - 1553
[Objective] To investigate the effect of Cox - 2 inhibitor (Celecoxib) on the receptor activation of NF-B ligand (RANKL) mRNA in peripheral blood mononuclear... 
Celecoxib
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 12/2016, Volume 375, Issue 26, pp. 2519 - 2529
BACKGROUND The cardiovascular safety of celecoxib, as compared with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), remains uncertain. METHODS... 
MEDICINE, GENERAL & INTERNAL | PAIN | METAANALYSIS | OSTEOARTHRITIS | CLINICAL-TRIAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | Celecoxib - adverse effects | Naproxen - adverse effects | Ibuprofen - therapeutic use | Humans | Middle Aged | Male | Risk | Celecoxib - therapeutic use | Naproxen - therapeutic use | Cyclooxygenase 2 Inhibitors - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Arthritis - drug therapy | Cyclooxygenase 2 Inhibitors - therapeutic use | Intention to Treat Analysis | Kidney Diseases - chemically induced | Cardiovascular Diseases - mortality | Female | Aged | Cardiovascular Diseases - chemically induced | Ibuprofen - adverse effects | Gastrointestinal Diseases - chemically induced | Care and treatment | Safety and security measures | Naproxen | Ibuprofen | Dosage and administration | Arthritis | Celecoxib | Diagnosis | Cardiovascular diseases | Risk factors | Cardiovascular disease | Side effects | Nonsteroidal anti-inflammatory drugs | Pain management | Myocardial infarction | Fees & charges | Hemorrhage | Pain | Motivation | Analgesics | Safety | Drug dosages | Cerebral infarction | Statistical analysis | Anemia | Committees | FDA approval | Patients | Manuscripts | Nonsteroidal antiinflammatory drugs | Rheumatoid arthritis | Collaboration | Osteoarthritis | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article